Evidence map›Paper›PMID 32448790›Full record

ArticleBMJ open2020

10-Valent pneumococcal non-typeable

Victor M Oguoma, Nicole Wilson, Kim Mulholland, Mathuram Santosham, Paul Torzillo, Peter McIntyre, Heidi Smith-Vaughan, Anne Balloch, Mark Chatfield, Deborah Lehmann and 9 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01735084 (Pneumococcal Conjugate Vaccine), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01735084 phase4completednot on this map

Pneumococcal Conjugate Vaccine (PCV) Schedules for the Northern Territory (NT): Randomised Controlled Trial of Booster Vaccines to Broaden and Strengthen Protection From Invasive and Mucosal Infections.

TypeinterventionalSponsorMenzies School of Health ResearchRan2013 to 2019Enrolled261ConditionsOtitis Media, Febrile Illness, Cough, Lower Respiratory Tract InfectionArmsPrevenar13, Synflorix
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 8 institutions in 1 country.

Victor M OguomaChild Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia.ORCID 0000-0001-9505-7197
Nicole WilsonChild Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia.
Kim MulhollandInfection and Immunity: Pneumococcal Research, Murdoch Childrens Research Institute, Parkville, Victoria, Australia.
Mathuram SantoshamCenter American Indian Health, John Hopkins School of Public Health, Baltimore, Maryland, USA.
Paul TorzilloRespiratory Medicine, Prince Alfred Hospital, Sydney, New South Wales, Australia.
Peter McIntyreDirector, National Centre for Immunisation Research and Surveillance, Sydney, New South Wales, Australia.
Heidi Smith-VaughanChild Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia.
Anne BallochPneumococcal Immunology, Murdoch Childrens Research Institute, Melbourne, Victoria, Australia.
Mark ChatfieldCerebral Palsy and Rehabilitation Research Centre, University of Queensland, Brisbane, Queensland, Australia.
Deborah LehmannDivision of Population Sciences, Telethon Institute for Child Health Research, West Perth, Western Australia, Australia.
Michael J BinksChild Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia.
Anne ChangChild Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia.
Jonathan CarapetisDirector, Telethon Kids Institute, Perth, Western Australia, Australia.
Vicki KrauseCentre for Disease Control, Department of Health, Darwin, Northern Territory, Australia.
Ross AndrewsChild Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia.
Tom SnellingInfectious Disease Implementation Research Team, Princess Margaret Hospital for Children, Perth, Western Australia, Australia.
Paul LicciardiInfections and Immunity: Pneumococcal Research, Murdoch Childrens Research Institute, Melbourne, Victoria, Australia.
Peter MorrisChild Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia.
Amanda Jane LeachChild Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia amanda.leach@menzies.edu.au.
Charles Darwin University · AUThe Kids Research Institute Australia · AUMurdoch Children's Research Institute · AUGovernment of Western Australia Department of Health · AUNational Centre for Immunisation Research & Surveillance · AURoyal Prince Alfred Hospital · AUThe University of Melbourne · AUThe University of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMETHODS AND ANALYSES: Our randomised controlled trial will enrol 270 Aboriginal children at 12 months of age to a booster dose of either PHiD-CV10 or PCV13. Children who completed the three-dose primary course schedules of PHiD-CV10 at 2, 4, 6 months of age; PCV13 at 2, 4, 6 months of age; or a combination schedule of PHiD-CV10 at 1, 2, 4 months of age plus PCV13 at 6 months of age are eligible. The co-primary assessor-blinded outcomes when the infants are 18 months of age are as follows: (a) IgG geometric mean concentration (GMC) and proportion with IgG ≥100 EU/mL for protein D, and (b) IgG GMC and the proportion with IgG ≥0.35 µg/mL for pneumococcal serotypes 3, 6A and 19A. Secondary immunogenicity comparisons of six primary and booster dose schedules of 10 shared serotypes at 18 months of age, nasopharyngeal carriage, all forms of otitis media, hearing loss and developmental milestones at 18, 24, 30 and 36 months of age will be reported. ETHICS AND DISSEMINATION: Ethics committees of NT Department of Health, Menzies, WA Department of Health and WA Aboriginal Health approved the study. Results will be presented to communities, at conferences and published in peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT01735084.

Indexed as

Health Services, IndigenousOtitis MediaPneumococcal InfectionsPneumococcal VaccinesAustraliaAustralian Aboriginal and Torres Strait Islander PeoplesChildChild, PreschoolHaemophilus influenzaeHumansImmunization, SecondaryInfantRandomized Controlled Trials as TopicVaccines, Conjugate13-valent pneumococcal vaccinePneumococcal VaccinesVaccines, Conjugatenasopharyngeal carriageotitis mediaPCV13PHiD-CV10

Identifiers

PMID32448790
PMCPMC7252982
OpenAlexW3028431467

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.